米托蒽醌对视神经脊髓炎患者外周血B淋巴细胞水平的影响
摘要
目的检测视神经脊髓炎（NMO）患者外周血B淋巴细胞水平,探讨米托蒽醌治疗NMO对患者外周血B淋巴细胞水平的影响。方法观察已确诊的复发频繁的28-55岁的NMO患者8例,每次使用米托蒽醌治疗时检测外周血B淋巴细胞水平,观察其水平变化。结果在观察期间,患者外周血中B淋巴细胞绝对值及百分比水平在治疗初期下降,持续治疗后外周血中B淋巴细胞比例水平有所上升。结论米托蒽醌治疗视神经脊髓炎的机制可能与调节外周血淋巴B细胞水平相关,外周血B淋巴细胞水平变化可作为视神经脊髓炎患者治疗过程中的评价指标。
出处
《航空航天医学杂志》
2016年第7期876-878,共3页
Journal of Aerospace medicine
参考文献12
-
1Oliver, Neuhaus, Bernd C, Kieseier, Hans - Peter, Har- tung. Therapeutic role of mitoxantrone in multiple sclerosis [J]. Pharmacology & therapeutics, 2006, 109 ( 1 - 2) : 198 - 209.
-
2ChunLei, Li, JingXia. Lipid composition and grafted PEG affect in vivo activity of liposomal mitoxantrone [ J ]. Inter- national journal of pharmaceutics, 2008,362 ( 1 - 2 ) : 60 - 66.
-
3Hamzehloo A, Etemadifar M. Mitoxantrone - induced car-diotoxicity in patients with multiple sclerosis [ J ]. Archives of Iranian Medicine, 2006,9(2) :111 - 114.
-
4Paola, Perini, Massimihano. Mitoxantrone versus cyclo- phosphamide in secondary - progressive multiple sclerosis [J]. Journal of neurology, 2006,253(8) :1034 - 1040.
-
5Syed A, Rizvi, Howard, Zwibel, Edward J, Fox. Mitox- antrone for multiple sclerosis in clinical practice[ J]. Neu- rology, 2004,63(12Suppl6) :S25 - S27.
-
6刘峥,董会卿,贾建平.米托蒽醌在治疗多发性硬化中的应用[J].中华神经科杂志,2012,45(10):749-751. 被引量：4
-
7姜寿峰,丁美萍.多发性硬化免疫调节治疗[J].医学综述,2009,15(20):3112-3115. 被引量：1
-
8Edan G, Comi G, Le Page E. Mitoxantrone prior to interfer- on beta - 1 b in aggressive relapsing multiple sclerosis : a 3 - year randomised trial[ J ]. Journal of Neurology, Neuro- surgery and Psychiatry , 2011,12(12) :56 -60.
-
9Marriott J, Miyasaki JM, Gronseth G, OConnor PW. Reportof the Therapeutics and Technology Assessment Subcom- mittee of the American Academy of Neurology [ J ]. Official Journal of the American Academy of Neurology , 2010,18 (18) :123 -130.
-
10Stroet, A, Hemmelmann, C. Incidence of therapy - related acute leukaemia in mitoxantrone -treated multiple sclero- sis patients in Germany [ J ]. Therapeutic advances in neurological disorders , 2012,2 ( 2 ) : 174 - 182.
二级参考文献45
-
1Coyle PK. Early treatment of multiple sclerosis to prevent neurologic damage [ J]. Neurology,2008,71 (24 Suppl 3 ) :3-7.
-
2Menge T, Weber MS, Hemmer B,et al. Disease-modifying agents for multiple sclerosis: recent advances and future prospects [ J ]. Drugs,2008 ,68(17) :2445-68.
-
3Dhib-Jalbut S. Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis[ J]. Neurology ,2002,58 ( 8 Suppl 4 ) : 3-9.
-
4Galboiz Y, Shapiro S, Lahat N ,et al. Matrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to interferon-β therapy in relapsing and secondary-progressive multiple sclerosis patients[ J]. Ann Neurol,2001,50(5 ) :443-451.
-
5Giorelli M, De Blasi A, Defazio G, et al. Differential regulation of membrane bound and soluble ICAM 1 in human endothelium and blood mononuclear cells: effects of interferon beta-ta [ J]. Cell Commun Adhes ,2002,9 ( 3 ) :259-272.
-
6Kapppos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-I b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes [ J]. Neruology, 2006,67 (10) : 1242-1249.
-
7Sorensen PS, Deisenhammer F, Duda P,et al. Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS task force on IFN-beta antibodies in multiple sclerosis [ J ]. Eur J Neurol,2005,12 ( 11 ) :817-827.
-
8Bayas A, Rieckmann P. Managing the adverse effects of interferonbeta therapy in multiple sclerosis [ J ]. Drug Sa, 2000,22 ( 2 ) : 149-159.
-
9Sellner J,Greeve I, Findling O, et al. Effect of interferon-beta and atorvastatin on Th1/Th2 cytokines in multiple sclerosis[ J]. Neurochem Int,2008,53(1/2) :17-21.
-
10Dressel A, Vogelgesang A, Brinkmeier H, et al. Glatiramer acetatespecific human CD8 ( + )T cells:increased IL-4 production in multiple sclerosis is reduced by glatiramer acetate treatment [ J ]. J Neuroimmunol,2006,181 ( 1/2 ) : 133-140.
共引文献3
-
1张黎.大剂量丙种球蛋白、甲基氢化泼尼松治疗神经系统自身免疫性疾病的观察与护理[J].吉林医学,2014,35(12):2687-2687. 被引量：4
-
2胡锦全,王云甫,孙延鹏,李贞艳.米托蒽醌治疗多发性硬化有效性和安全性的Meta分析[J].现代医学,2014,42(5):482-486. 被引量：2
-
3乔雨晨,孟茜.米托蒽醌治疗特发性炎性脱髓鞘疾病病人的护理研究进展[J].护理研究（中旬版）,2015,29(12):4371-4372. 被引量：1
-
1耿江.米托蒽醌——治疗多发性硬化症新选择[J].中华医学信息导报,2003,18(6):12-12.
-
2神经病学文献[J].世界核心医学期刊文摘（眼科学分册）,2006,2(11):1-2.
-
3刘萍,边强.多发性硬化症的药物治疗进展[J].中国医院用药评价与分析,2002,2(3):173-175.
-
4抗癌药物米托蒽醌对多发性硬化症有疗效[J].上海医药,2003,24(3):141-141.
-
5乔清.视神经脊髓炎的相关研究进展[J].中国医学创新,2011,8(19):192-195.
-
6盛明,刘慧霞,张燕柳.米托蒽醌治疗进展型多发性硬化症的疗效观察[J].慢性病学杂志,2014,14(2):143-144. 被引量：3
-
7胡锦全,王云甫,孙延鹏,李贞艳.米托蒽醌治疗多发性硬化有效性和安全性的Meta分析[J].现代医学,2014,42(5):482-486. 被引量：2
-
8巨红燕,冯灵,陈静.多发性硬化患者使用米托蒽醌的护理体会[J].护理实践与研究,2013,10(10):82-83. 被引量：4
-
9陈颖,王志海.米托蒽醌治疗进展型多发性硬化的疗效及安全性观察[J].广东医学院学报,2011,29(4):396-397. 被引量：2
-
10徐玉,刘静,王秀丽,王颖,赵平平,郭力.多发性硬化治疗研究新进展[J].临床荟萃,2007,22(15):1135-1138. 被引量：1
